StockData
Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc. (CTKB) stock

CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/309% below fair value
$5.70+0.07 (+1.24%)

Close on Nov 17, 2026Market cap $740.91MP/E –Yield –

Cytek Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Cytek Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$6.04M, down 139.7% year over year. For fiscal 2025 it was -$4.69M, down 118.5% from the year before. The highest annual figure on record is $25.38M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$4.69M-118.5%
FY2024Dec 31, 2024$25.38M+380.6%
FY2023Dec 31, 2023$5.28M–
FY2022Dec 31, 2022-$12.23M-364.2%
FY2021Dec 31, 2021$4.63M-69.5%
FY2020Dec 31, 2020$15.16M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.37M+1165.7%
Q1 FY2026Mar 31, 2026-$2.74M–
Q4 FY2025Dec 31, 2025-$771.00K-138.6%
Q3 FY2025Sep 30, 2025-$3.90M-129.5%
Q2 FY2025Jun 30, 2025$108.00K-98.3%
Q1 FY2025Mar 31, 2025-$125.00K-103.2%
Q4 FY2024Dec 31, 2024$2.00M-79.0%
Q3 FY2024Sep 30, 2024$13.22M–
Q2 FY2024Jun 30, 2024$6.20M–
Q1 FY2024Mar 31, 2024$3.96M+38.5%
Q4 FY2023Dec 31, 2023$9.51M+53.6%
Q3 FY2023Sep 30, 2023-$4.24M–
Q2 FY2023Jun 30, 2023-$2.85M–
Q1 FY2023Mar 31, 2023$2.86M–
Q4 FY2022Dec 31, 2022$6.19M+13.7%
Q3 FY2022Sep 30, 2022-$7.50M-746.3%
Q2 FY2022Jun 30, 2022-$9.44M–
Q1 FY2022Mar 31, 2022-$1.48M-176.5%
Q4 FY2021Dec 31, 2021$5.45M-53.2%
Q3 FY2021Sep 30, 2021$1.16M-47.0%
Q2 FY2021Jun 30, 2021-$3.91M–
Q1 FY2021Mar 31, 2021$1.94M–
Q4 FY2020Dec 31, 2020$11.64M–
Q3 FY2020Sep 30, 2020$2.19M–

More Cytek Biosciences figures

See a number that looks wrong?